Patients with a high tumor burden may develop tumor lysis syndrome. Tumor lysis syndrome consists of at least 2 metabolic abnormalities, which may include hyperkalemia, hyperphosphatemia, or hyperuricemia. The goal of standard therapy is to prevent tumor lysis syndrome. Prophylactic therapy includes hydration, alkalinization, and treatment to lower uric acid with either allopurinol or rasburicase. Other metabolic abnormalities are treated as they occur.
Schifter T, Cohen A, Lewinski UH. Severe tumor lysis syndrome following splenic irradiation. Am J Hematol. 1999;60:75-76.
3.
Lobe TE, Karkera MS, Custer MD, et al. Fatal refractory hyperkalemia due to tumor lysis during primary resection for hepatoblastoma. J Pediatr Surg. 1990;25:249-250.
4.
Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors: a case report and review of the literature. Cancer Chemother Pharmacol. 2003;51:187-192.
5.
Annemans L, Moeremans K, Lamotte M.Pan-European multi-centre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer. 2003;11:249-257.
6.
Navolanic PM, Pui C-H, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome—a meeting report, Dallas, Texas, January 2002. Leukemia. 2003;17:499-514.
7.
Van Der Klooster JM, Van Der Wiel HE, Van Saase JLCM, et al. Asystole during combination chemotherapy for non-Hodgkin’s lymphoma: the acute tumor lysis syndrome. Neth J Med. 2000;56:147-152.
Dunlay RW, Camp MA, Allon M, et al. Calcitriol in prolonged hypocalcemia due to tumor lysis syndrome. Ann Intern Med. 1989;110:162-164.
10.
Boles JM, Dutel JL, Briere J.Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of acute lymphoblastic leukemia. Cancer. 1984;53:2425-2429.
11.
Monballyu J, Zachee J, Verberckmoe SR, et al. Transient acute renal failure due to tumor lysis induced severe phosphate load in a patient with Burkitt lymphoma. Clin Nephrol. 1984;22:47-51.
12.
Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206-212.
13.
Ablin A, Stephens BG, Hirata T, et al. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt’s lymphoma treated with chemotherapy and allopurinol. Metabolism. 1972;21:771-778.
14.
Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones: a rare complication of allopurinol therapy. N Engl J Med. 1969;280:426-427.
15.
Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome: a review of 37 patients with Burkitt’s lymphoma. Am J Med. 1980;68:486-491.
16.
Stapleton FB, Strother DR, Roy S, et al. Acute renal failure at the onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988;82:863-869.
17.
Haas M, Ohler L, Watzke H, et al. The spectrum of acute renal failure in tumour lysis syndrome. Nephrol Dial Transplant. 1999;14:776-779.
18.
Tsokos GC, Ballow JE, Spiegel RJ, et al. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine. 1981;60:218-229.
19.
Hande KR, Hixson CV, Chabner BA. Post chemotherapy purine excretion in patients receiving allopurinol. Cancer Res. 1981;41:2273-2279.
20.
Ten Harkel ADJ, Kist-Van Holther JE, Vanweel M, et al. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol. 1998;31:27-28.
21.
Band PR, Silverberg DS, Henderson JF, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 1970;283:354-357.
22.
Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use allopurinol, a xanthine oxidase inhibitor. JAMA. 1965;193:89-94.
23.
DeConti RC, Calabresi P.Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med. 1966;274:481-486.
24.
Muggia FM, Ball TJ, Ultmann JE. Allopurinol in the treatment of neoplastic disease complicated by hyperuricemia. Arch Intern Med. 1967;120:12-18.
25.
Krakoff H, Murphy ML. Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor. Pediatrics. 1968;41:52-56.
26.
Smalley RV, Guaspari A, Haase-Statz S, et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000;18:1758-1763.
27.
Ducros J, Saingra S, Rampal M, et al. Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient. Clin Nephrol. 1991;35:89-90.
28.
Pui C-H, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813-1816.
29.
Pui C-H, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19:697-704.
30.
Pui C-H, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15:1505-1509.
31.
Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.
32.
Pichette V, Leblane M, Bonnandeux A, et al. High dialysate flow rate in continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis. 1994;23:591-596.
33.
Heney D, Essex-Cater A, Brocklebank JT, et al. Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome. Pediatr Nephrol. 1990;4:245-247.
34.
Saccente SL, Kohaut EC, Berkow RL. Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Pediatr Nephrol. 1995;9:569-573.
35.
Jaing T-H, Hsueh C, Tain Y-L, et al. Tumor lysis syndrome in an infant with langerhans cell histiocytosis successfully treated using continuous arteriovenous hemofiltration. J Pediatr Hematol Oncol. 2001;23:142-144.
36.
Sakarcan A, Quigley R.Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol. 1994;8:351-353.
37.
Cardinal Health. Medispan. Available at: www.cardinal.com. Accessed October 12, 2004.
